189 related articles for article (PubMed ID: 19798057)
1. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin.
Lahtz C; Stranzenbach R; Fiedler E; Helmbold P; Dammann RH
J Invest Dermatol; 2010 Feb; 130(2):620-2. PubMed ID: 19798057
[No Abstract] [Full Text] [Related]
2. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H
J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
4. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
7. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis.
Yamamoto Y; Matsusaka K; Fukuyo M; Rahmutulla B; Matsue H; Kaneda A
Cancer Med; 2020 Oct; 9(19):7194-7204. PubMed ID: 32406600
[TBL] [Abstract][Full Text] [Related]
8. Aberrant DNA methylation in malignant melanoma.
Schinke C; Mo Y; Yu Y; Amiri K; Sosman J; Greally J; Verma A
Melanoma Res; 2010 Aug; 20(4):253-65. PubMed ID: 20418788
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic markers of prognosis in melanoma.
Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
Methods Mol Biol; 2014; 1102():481-99. PubMed ID: 24258994
[TBL] [Abstract][Full Text] [Related]
10. PTEN Methylation Dependent Sinonasal Mucosal Melanoma.
Lee SH; Roh MR; Kang B; Park KH; Kim SH; Lee SE; Rha SY
Cancer Res Treat; 2016 Apr; 48(2):853-8. PubMed ID: 25797573
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations of PTEN in human melanoma.
Aguissa-Touré AH; Li G
Cell Mol Life Sci; 2012 May; 69(9):1475-91. PubMed ID: 22076652
[TBL] [Abstract][Full Text] [Related]
12. Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Kaehler KC; Politz O; Henderson D; Ulbrich HF; Hauschild A; Mund C; Egberts F
Melanoma Res; 2015 Jun; 25(3):225-31. PubMed ID: 25919928
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers in malignant cutaneous melanoma: gift horse or one-trick pony?
Martinez SR; Hoon DS
J Cell Biochem; 2005 Oct; 96(3):473-83. PubMed ID: 16088931
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic biomarkers in skin cancer.
Greenberg ES; Chong KK; Huynh KT; Tanaka R; Hoon DS
Cancer Lett; 2014 Jan; 342(2):170-7. PubMed ID: 22289720
[TBL] [Abstract][Full Text] [Related]
15. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma.
Huang KH; Huang SF; Chen IH; Liao CT; Wang HM; Hsieh LL
Clin Cancer Res; 2009 Jun; 15(12):4174-80. PubMed ID: 19509163
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA regulation of melanoma progression.
Bonazzi VF; Stark MS; Hayward NK
Melanoma Res; 2012 Apr; 22(2):101-13. PubMed ID: 22209751
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of the PTEN gene in melanoma.
Mirmohammadsadegh A; Marini A; Nambiar S; Hassan M; Tannapfel A; Ruzicka T; Hengge UR
Cancer Res; 2006 Jul; 66(13):6546-52. PubMed ID: 16818626
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas.
Cesinaro AM; Sartori G; Migaldi M; Schirosi L; Pellacani G; Collina G; Maiorana A
Pathology; 2012 Jun; 44(4):313-7. PubMed ID: 22544212
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
[TBL] [Abstract][Full Text] [Related]
20. Clinical Snippets.
J Invest Dermatol; 2016 May; 136(5):888. PubMed ID: 27140323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
